anti-CD22-CAR-transduced T cells（Southwest Hospital）

N/A

Report date: 2026/01/21 20:00:47

Base Information

Drug Nameanti-CD22-CAR-transduced T cells（Southwest Hospital）
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionCD22 modulatorsT lymphocyte replacements
TargetsCD22
Therapy Area/IndicationsLymphomaLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesThe Southwest Hospital of AMU
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe Southwest Hospital of AMU
Active IndicationsN/A
Inactive IndicationsLymphomaLeukemia

Other Information

ATC CodeN/A
Related LinksN/A